News | April 06, 2026
Red Nucleus acquires Bridge Medical Consulting with advisory support from VERTICES PARTNERS
As part of the deal, Red Nucleus also gains indirect ownership of the company’s Indian arm
As part of the deal, Red Nucleus also gains indirect ownership of the company’s Indian arm
Parliament clears reform bill replacing jail terms for procedural lapses with graded monetary penalties across key health laws
Lilly has long voiced concerns over mass-compounded knockoffs of its tirzepatide medicines, Mounjaro and Zepbound
One task, one interaction, one pair, experts advocate
The conflict is also triggering a widening public health emergency
The Phase 1 dose-escalation trial enrolled 25 evaluable patients and was designed to determine the recommended dose of LYMPHIR
The acquisition of Biocare enhances Agilent’s pathology portfolio and reflects our strategy to drive long-term growth
Under the deal, Hims & Hers will offer patients access to FDA-approved versions of Ozempic and Wegovy at the same self-pay prices available through other telehealth platforms
Moderna will appeal to the Federal Circuit to assert that its government-contractor immunity limits liability under federal law
Fenebrutinib has the potential to become the first and only high-efficacy oral, brain-penetrant treatment for both RMS and PPMS, showing a profound benefit on relapsing and progressive disease biology
Subscribe To Our Newsletter & Stay Updated
